Adaptimmune Therapeutics plc (NASDAQ: ADAP) today reported financial results and provided a business update for the second quarter ended June 30, 2025.

As of June 30, 2025, Adaptimmune had cash and cash equivalents of $26.1 million and Total Liquidity of $26.1 million, compared to $91.1 million and $151.6 million respectively, as of December 31, 2024.

Revenue for the three months ended June 30, 2025, was $13.7 million respectively, compared to $128.2 million and $133.9 million for the same periods in 2024.

Said CEO Adrian Rawcliffe, "The launch of TECELRA continued to accelerate through Q2 with an increase of over 150% in patients invoiced and in revenue. The full network of ATCs is close to completion with 30 now accepting referrals.

"Our manufacturing organization continues to deliver with a 100% commercial manufacturing success rate through to the end of Q2. The transaction with US WorldMeds will ensure that patient access to TECLRA continues and also places lete-cel in capable hands leading up to its planned launch in 2026. As we noted when we announced the transaction on July 28, this deal follows an extensive review of strategic alternatives and represents the best path forward for Adaptimmune, our patients and stakeholders."

ADAP shares took on eight cents to $2.60.

COMTEX_468013905/2559/2025-08-13T10:12:43